Draig Therapeutics’ lead drug is designed to safely target the AMPA receptor as a way of mediating the interplay between two neurotransmitters whose imbalance is associated with mood disorders. The startup is one of several that have recently raised mega rounds of financing to support programs in the clinic or entering clinical testing.
The Alzheimer’s disease drugs that have reached the market in the past two years are antibodies designed to break up amyloid plaques. Vigil Neuroscience brings to Sanofi a different approach: an oral small molecule designed to activate microglia, immune cells that play a key role in brain health.
Healthcare is drowning in chaos—from scattered data to burnout-inducing tasks. Discover how smarter workflows and real-time insights can rescue care teams and transform patient outcomes.
A planned interim clinical trial analysis found Praxis Precision Medicines drug ulixacaltamide was unlikely to succeed as a treatment for essential tremor. But Praxis is continuing two late-stage tests of the drug; data are expected in the third quarter of 2025.
Johnson & Johnson’s agreement to acquire Intra-Cellular Therapies brings Caplyta, which is projected to become a blockbuster seller across several neurological indications. In other M&A news, GSK and Eli Lilly each struck deals to fill their cancer drug pipelines.
Lundbeck says Longboard Pharmaceuticals’ drug, bexicaserin, has potential applications in a range of rare epilepsies. Last month, the biotech began a Phase 3 clinical trial testing the drug in Dravet syndrome.
Bristol Myers Squibb’s Cobenfy treats schizophrenia by going after a different target than currently available antipsychotic drugs, which is intended to offer better efficacy and safety. The drug came from the pharma giant’s $14 billion acquisition of Karuna Therapeutics.
Explore top PTSD treatment centers in Arizona, offering personalized care, holistic therapies and expert support to help individuals heal and reclaim their lives.
By prioritizing user-centric design, responsible data practices, and evidence-based solutions neurotech companies can not only drive user adoption but also foster long-term brand loyalty.
AbbVie’s alliance with Gilgamesh Pharmaceuticals is pursuing next-generation psychiatric medications. The companies aim to bring patients drugs that offer the benefit of psychedelics but with a better side effect profile.
From diagnostics to treatment methodologies, BCI technology can unravel new dimensions of understanding and intervention, fundamentally altering the landscape of patient care.
Alto Neuroscience will apply the IPO proceeds toward clinical tests of its psychiatric drugs in patients who exhibit certain biomarkers. The company's two most advanced programs are depression drugs in mid-stage development.
Break down the silos. Take control of your provider data.
Biogen has returned its Aduhelm rights to Neurimmune, the company that initially developed the antibody Alzheimer’s disease drug. But Biogen isn’t abandoning Alzheimer’s, and its pipeline includes drugs that take other approaches to the neurodegenerative disorder.
Longboard Pharmaceuticals’ epilepsy drug candidate bexicaserin met the main efficacy goal of its Phase 1b/2a study along with safety data suggesting a potential edge over current treatments. With Longboard now preparing to advance to Phase 3 testing, its stock price soared more than 300%.
Merck’s acquisition of Caraway Therapeutics adds programs for genetically defined neurodegenerative diseases. One of those programs addresses a target that was the focus of a different startup purchased by Merck in 2019.
Roche is paying $50 million up front to begin a drug R&D alliance with Monte Rosa Therapeutics, a biotech whose molecular glue technology could address targets previously deemed undruggable. It’s Roche’s second such deal in the past month.
Biohaven’s bid to bring to market the first drug for rare neuromuscular disorder spinocerebellar ataxia has hit a setback. The FDA is refusing to review the drug’s application, a decision that could indicate the agency wants another clinical trial.